canyon landscape

Ampreloxetine (TD-9855) for Treating snOH in PAF

A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and snOH with up to 4 weeks of treatment.

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and snOH. The study consists of 3 periods: (i) 2-week screening, (ii) 4-week randomized treatment, and (iii) 2-week follow up.

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Total Participants
188
Primary Sponsor
Theravance Biopharma